pharmaceutical-investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
pharmaceutical-investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
CoTec Forms Subsidiary, CoTec Copper, To Accelerate Investment Activities In Copper Tailings and Copper Sulfide Deposits
